Cambridge Healthtech Institute to Host Its Second Annual Collaborative Innovation in Biomedicine Conference

Share Article

Strategies and Best Practices for Pre-Competitive Sharing of Data, Results and Costs

Given the number of challenges that the industry is facing

Cambridge Healthtech Institute will host its second annual Collaborative Innovation in Biomedicine conference on June 14-16, 2010 in Philadelphia, PA. The biomedical industry is under enormous pressure to produce faster results, while also finding ways to reduce costs. Examples abound in one industry after another of how researchers have gained tremendous advantages by collaborating on pre-competitive efforts, but such efforts have been limited in biomedical research, where researchers often find it difficult to openly share data within their own organization, much less with competitors. This conference aims to bring together a number of experts with practical experience in organizing, managing, funding, and getting results from pre-competitive collaborative projects. Speakers will talk from first-hand experience about what works and what doesn't as the program explores the most important new models, key issues, challenges and best practices of Collaborative Innovation in Biomedicine.

"Given the number of challenges that the industry is facing," says Phillips Kuhl, President of Cambridge Healthtech Institute, "There is clearly a need for new models and approaches. A key goal of the program is to provide attendees with a number of key strategies for identifying when and how collaborative innovation can and should be encouraged, as well as when such efforts are less likely to produce useful results."

The conference program will deal with topics such as case studies of successful consortia and collaborations; strategies for dealing with the challenge of shared intellectual property; strategies and technology for facilitating data sharing; novel approaches for identifying collaborative information and partners; collaborative development and evaluation of new technology and software; and more. The conference will feature speakers with first-hand experience in setting up and running successful consortia.

Featured speakers include a number of representatives from large pharma: Jackie Hunter, Ph.D., Senior Vice President, Science Environment Development, GlaxoSmithKline; Robin Spencer, Ph.D., Senior Fellow, Research Centers of Emphasis, Pfizer, Inc.; Stefan J. Platz, Ph.D., Head, Toxicology & Pathology, F. Hoffman-LaRoche Ltd.; David Cook, Ph.D., Global Safety Assessment, AstraZeneca Pharmaceuticals; Bryn Williams-Jones, Ph.D., Associate Research Fellow; Head, eBiology, Pfizer; and Ramesh Durvasula, Ph.D., Director, Chemistry Informatics, Research Informatics & Automation, Bristol-Myers Squibb.

In addition, case studies of emerging consortia-based models and best practices will be presented by representatives from consortia, not-for-profit and academics, as well as executives from technology/biotechnology companies: Eric Thompson, Ph.D., Assistant Director, Predictive Safety Testing Consortium, Critical Path Institute; Robert Porter-Lynch, Ph.D., CEO, The Warren Group; Managing Partner, System of Trust, LLC; Les Jordan, Chief Technology Strategist, Microsoft Life Sciences; Sean Ekins, Ph.D., Collaborations Director, Research & Development, Collaborative Drug Discovery; Jean-Robert Ioset, Professor, Project Coordinator, Research & Development, Drugs for Neglected Diseases initiative (DNDi); Max Fehlmann, Ph.D., President & CEO, Quebec Consortium of Drug Discovery; Mariana Guergova-Kuras, Ph.D., Director of Research, Biosystems International; Shawnmarie Mayrand-Chung, Ph.D., NIH Director for The Biomarkers Consortium & Senior Advisor to The Biomarkers Consortium; Syril D. Pettit, Ph.D., MEM, Associate Director, HESI, ILSI; John Overington, Ph.D., Team Leader, Chemogenomics, EMBL-EBI, Wellcome Trust Genome Campus; and Sandor Szalma, Ph.D., Senior Research Fellow, Research & Development Informatics, Centocor R&D, Inc.

The Collaborative Innovation in Biomedicine conference is immediately followed by CHI's inaugural Encouraging Development of Therapeutics for Neglected Diseases conference being held June 16-17, 2010. Cambridge Healthtech Institute offers package pricing to attendees interested in participating in both conferences.

Please visit http://www.healthtech.com/cbi for more information.

About Cambridge Healthtech Institute (CHI)
Founded in 1992, Cambridge Healthtech Institute (CHI) (http://www.chicorporate.com) is the industry leader offering the preeminent source of information to the leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, and Cambridge Healthtech Media Group.

Contact: Kaushik Chaudhuri
Cambridge Healthtech Institute
(781) 972-5419
kchaudhuri(at)healthtech(dot)com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tracey Fielding

781-972-5429
Email >